Evidence map›Paper›PMID 35122035›Full record

ReviewNature cancer2020

Circulating tumor DNA and liquid biopsy in oncology.

David W Cescon, Scott V Bratman, Steven M Chan, Lillian L Siu

3 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 332 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
332citing papers in PubMed, 12 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05066776 terminatednot on this mapstarted 2021, after this paper: background citation

Liquid Biopsy in Combination With PET/CT Versus PET/CT Alone in Diagnosis of Small Lung Nodules

TypeobservationalSponsorPalo Alto Veterans Institute for ResearchRan2021 to 2023Enrolled31ConditionsLung Cancer, Solitary Pulmonary Nodule, Multiple Pulmonary Nodules
NCT06388967 recruitingnot on this mapstarted 2023, after this paper: background citation

Early Detection of Pancreatic Cancer: Prospective Study

TypeobservationalSponsorCity of Hope Medical CenterRan2023 to 2030Enrolled2,000ConditionsPancreatic Cancer, Pancreatic Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal AdenocarcinomaArmsPANcreatic cancer Exosome Early detectiON (PANXEON)
NCT06717295 recruitingnot on this mapstarted 2025, after this paper: background citation

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling

TypeobservationalSponsorJavier ToledoRan2025 to 2028Enrolled6,000ConditionsBrest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate CancersArmsDiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
3 · Its place in the literature

Who cites it

332 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. Pooled it
  2. Diagnostic accuracy of next-generation sequencing (NGS) for identifying actionable mutations in advanced non-small cell lung cancer: Systematic Review and Meta-Analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  15. Trial
  16. Review
  17. Article
  18. Beyond the Needle: Is Liquid Biopsy the Future of Veterinary Medicine?International journal of molecular sciences · 2026
    Review
  19. Article
  20. Article

272 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

David W CesconDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.ORCID http://orcid.org/0000-0002-1080-0998
Scott V BratmanDepartment of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.ORCID http://orcid.org/0000-0001-8610-4908
Steven M ChanDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
Lillian L SiuDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada. lillian.siu@uhn.ca.ORCID http://orcid.org/0000-0002-3500-0540

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the capabilities of this technology as a diagnostic test. The full potential of ctDNA liquid biopsy in the diagnosis, characterization and management of solid and hematological malignancies will be uncovered through interventional clinical trials evaluating clinical utility. In this Review, we discuss the current landscape of ctDNA liquid-biopsy applications across the cancer continuum and highlight opportunities for clinical investigation.

Indexed as

Circulating Tumor DNANeoplasmsBiomarkers, TumorHumansLiquid BiopsyBiomarkers, TumorCirculating Tumor DNA

Identifiers

PMID35122035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.